¶ ACTIV-6
.png)
ACTIV-6, officially ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications, is an American study of repurposed drugs to treat COVID-19. The four drugs included in the study are ivermectin, fluvoxamine, fluticasone and montelukast.
It is part of the larger Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.
The study officially began on June 8, 2021, and is scheduled for completion in March 2024.[1]
¶ History
The study was first posted to ClinicalTrials.gov on May 13, 2021.[1:1]
¶ Funding
ACTIV-6 is funded by:[2]
- Biomedical Advanced Research and Development Authority (BARDA)
- National Center for Advancing Translational Sciences (NCATS)
- Office of the Assistant Secretary for Preparedness and Response]
- Vanderbilt University Medical Center
¶ External links
Naggie, S., National Center for Advancing Translational Sciences (NCATS), & Vanderbilt University Medical Center. (2023, May 4). ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications. ClinicalTrials.gov. https://web.archive.org/web/20230518153157/https://clinicaltrials.gov/ct2/show/NCT04885530 ↩︎ ↩︎
Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Slandzicki, A. J., Lim, S. C., Cohen, J., Kavtaradze, D., Amon, A. P., Gabriel, A., Gentile, N., Felker, G. M., Jayaweera, D., McCarthy, M. W., Sulkowski, M., Rothman, R. L., Wilson, S., DeLong, A., Remaly, A., & Wilder, R. (2023). Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. JAMA, 329(11), 888-897. https://doi.org/10.1001/jama.2023.1650 ↩︎